Latest Articles
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer - TipRanks
BioNTech Reports Strong Phase 2 Data for HER2-Targeted ADC in Recurrent Endometrial Cancer TipRanks
Published: April 13, 2026, 12:29 p.m.
PORTAL MADNESS: Scott Drew STEALS Elite Kentucky Target, He Wants to DESTROY Mark Pope? - newscentermaine.com
PORTAL MADNESS: Scott Drew STEALS Elite Kentucky Target, He Wants to DESTROY Mark Pope? newscentermaine.com
Published: April 13, 2026, 1:54 a.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KELO-AM
GSK sees blockbuster potential in targeted cancer therapy after promising early data KELO-AM
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - KFGO
GSK sees blockbuster potential in targeted cancer therapy after promising early data KFGO
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WKZO
GSK sees blockbuster potential in targeted cancer therapy after promising early data WKZO
Published: April 12, 2026, 8:44 p.m.
GSK sees blockbuster potential in targeted cancer therapy after promising early data - WSAU
GSK sees blockbuster potential in targeted cancer therapy after promising early data WSAU
Published: April 12, 2026, 8:44 p.m.
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug - MedPage Today
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug MedPage Today
Published: April 12, 2026, 8:01 p.m.
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK US
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK US
Published: April 12, 2026, 2:25 p.m.
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers - GSK
GSK presents positive data for B7-H4-targeted ADC in gynecological cancers GSK
Published: April 12, 2026, 2:25 p.m.
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers - National Today
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as Highly Expressed, Clinically Relevant Target for Gynecologic Cancers National Today
Published: April 10, 2026, 4:35 p.m.
Link copied to clipboard!